{
    "id": 20292,
    "cites": 38,
    "cited_by": 3,
    "reference": [
        "Berle, Adolf, and Gardiner Means. 1932. The Modern Corporation and Private Property. New York: Harcourt Brace.",
        "Berndt, Ernst R., and Murray L. Aitken. 2011. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Brand Loyalty, Generic Entry and Price Competition in Pharmaceuticals in the Quarter Century after the 1984 Waxman-Hatch Legislation.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d International Journal of the Economics of Business 18(2): 177-201.",
        "Berndt, Ernst, R., Rena M. Conti, and Haiden A. Huskamp. 2001. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093The Effect of FDA Advisories on Branded Pharmaceutical Firms&apos; Valuations and Promotion Efforts.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Working Paper no. 17528. National Bureau of Economic Research, Cambridge, MA.",
        "Brown, Stephen J., and Jerold B. Warner. 1985. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Using Daily Stock Returns: The Case of Event Studies.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Journal of Financial Economics 14: 3-31.",
        "Bulow, Jeremy. 2004. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093The Gaming of Pharmaceutical Patents.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d 145-187 in Innovation Policy and the Economy, edited by Adam B. Jaffe, Josh Lerner, and Scott Stern. Cambridge: MIT Press.",
        "Campbell, John, Andrew Lo, and A. Craig Mackinlay. 1997. The Econometrics of Financial Markets. Princeton, NJ: Princeton University Press.",
        "Congressional Budget Office. 1998. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093How Increased Competition from Generic Drugs has Affected Prices and Returns in the Pharmaceutical Industry.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d http://www.cbo.gov/publication/10938 (last updated July 1, 1998).",
        "Cotter, Thomas F. 2003. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Refining the \u00c3\u00a2\u00e2\u0082\u00ac\u00cb\u009cPresumptive Illegality\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0084\u00a2 Approach to Settlements of Patent Disputes Involving Reverse Payments: A Commentary on Hovenkamp, Janis & Lemley.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Minnesota Law Review 87(6): 1789-1816.",
        "Cotter, Thomas F. 2004. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Antitrust Implications of Patent Settlements Involving Reverse Payments: Defending a Rebuttable Presumption of Illegality in Light of Some Recent Scholarship.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Antitrust Law Journal 71(3): 1069\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c097.",
        "Dickey, Brett, Jonathan Orszag, and Laura Tyson. 2010. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093An Economic Assessment of Patent Settlements in the Pharmaceutical Industry.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Annals of Health Law 19(2): 367-400.",
        "Ellison, Sara F., and Wallace P. Mullin. 2001. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Gradual Incorporation of Information: Pharmaceutical Stocks and the Evolution of President Clinton&apos;s Health Care Reform.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Journal of Law and Economics 44: 89-129.",
        "Fama, Eugene F., and Kenneth R. French. 1993. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Common Risk Factors in Returns on Stocks and Bonds.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Journal of Financial Economics 33: 3\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c56.",
        "Federal Trade Commission. 2007. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093FTC Provides Senate Testimony on Anticompetitive Patent Settlements in the U.S. Pharmaceutical Industry.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d http://www.ftc.gov/news-events/pressreleases /2007/01/ftc-provides-senate-testimony-anticompetitive-patent-settlements (last updated January 17, 2007).",
        "Federal Trade Commission. 2010. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Pay-for-Delay: How Drug Company Pay-Offs Cost Consumers Billions.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d http://www.ftc.gov/reports/pay-delay-how-drug-company-payoffs -cost-consumers-billions-federal-trade-commission-staff (last updated January 2010).",
        "Federal Trade Commission. 2011. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Authorized Generic Drugs: Short-Term Effects and LongTerm Impact.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d http://www.ftc.gov/opa/2011/08/genericdrugs.shtm (last updated August 31, 2011).",
        "Federal Trade Commission. 2013. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Agreements Filed with the Federal Trade Commission under the Medicare Prescription Drug, Improvement, and Modernization Act of 2003: Overview of Agreements Filed in Fiscal Year 2012: A Report by the Bureau of Competition.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d http://www.ftc.gov/reports/agreements-filed-federal-trade-commissionunder -medicare-prescription-drug-improvement (last updated January 2013).",
        "Food and Drug Administration. 2014. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Paragraph IV Patent Certifications.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d http://www.fda.gov/drugs/developmentapprovalprocess/howdrugsaredevelopedandappro ved/approvalapplications/abbreviatednewdrugapplicationandagenerics/ucm047676.htm.",
        "Girotra, Karen, Christian Terwiesch, and Karl T. Ulrich. 2007. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Valuing R&D Projects in a Portfolio: Evidence from the Pharmaceutical Industry.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Management Science 53(9): 1452-1466.",
        "Green, Daniel. 1995. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Glaxo Shares Rise as it Settles Patent Case.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Financial Times, October 24.",
        "Greene, Adam, and D. Dewey Steadman. 2010. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Pharmaceuticals: Analyzing Litigation Success Rates.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d http://amlawdaily.typepad.com/pharmareport.pdf.",
        "Generic Pharmaceutical Association. 2006. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Re: Authorized Generic Drug Study: FTC Project No. P062105.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d http://www.ftc.gov/os/comments/genericdrugstudy3/062806gpha.pdf.",
        "Hemphill, C. Scott. 2009. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093An Aggregate Approach to Antitrust: Using New Data and Rulemaking to Preserve Drug Competition.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Columbia Law Review 109(4): 629-687.",
        "Hemphill, C. Scott. 2014. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Unjustified Delays in Generic Drug Competition.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Organization for Economic Cooperation and Development, White Paper on Generic Pharmaceuticals, DAF/COMP/WD(2014)76.",
        "IMS Institute for Healthcare Informatics. 2013. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Impact of Patent Settlements on Drug Costs: Estimation of Savings.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d http://www.imshealth.com/deployedfiles/imshealth/Global/Content/Corporate/IMS%20In stitute/Impact_of_Patent_Settlements_on%20Drug_Costs.pdf (last updated June 2013).",
        "Jacobo-Rubio, Ruben, John L. Turner, and Jonathan Williams. 2013. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Pharmaceutical Patent Litigation: Measuring the Value of Generic Entry Rights and Brand Deterrence.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Unpublished manuscript. University of Georgia, Department of Economics, June.",
        "Koijen, Ralph S.J., Tomas J. Philipson, and Harald Uhlig. 2014. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Financial Health Economics.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Working Paper no. 20075. National Bureau of Economic Research, Cambridge, MA.",
        "Leffler, Keith, and Cristofer Leffler. 2003. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093The Probabilistic Nature of Patent Rights: In Response to Kevin McDonald.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Antitrust 17: 77-83.",
        "Meland, Marius. 2005. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Kos, Barr Settle Niaspan Patent Litigation with Unusual Deal.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d http://www.law360.com/articles/3283/kos-barr-settle-niaspan-patent-litigation-withunusual -deal (last updated April 13, 2005).",
        "Panattoni, Laura E. 2011. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093The Effect of Paragraph IV Decisions and Generic Entry before Patent Expiration on Brand Pharmaceutical Firms.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Journal of Health Economics 30(1): 126-145.",
        "P\u00c3\u0083\u00c2\u00a9rez-Rodr\u00c3\u0083\u00c2\u00adguez, Jorge V., and Beatriz G.L. Valcarcel. 2012. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Do Product Innovation and News about the R&D Process Produce Large Price Changes and Overreaction? The Case of Pharmaceutical Stock Prices.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Applied Economics 44(17): 2217-2229.",
        "PR Newswire. 2006. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Par Pharmaceutical Announces Agreement with GlaxoSmithKline to Settle Imitrex Injection Patent Litigation: Settlement Agreement with GSK Resolves Imitrex Injection Patent Litigation and Permits Par to Launch Generic Version in 2008. November 13.",
        "Shapiro, Carl. 2003b. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Antitrust Limits to Patent Settlements.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d RAND Journal of Economics. 34(2): 391-411.",
        "Stata. 2013. Stata Base Reference Manual, Release 13. College Station, TX: Stata Press.",
        "Tcak, Paula A. 1999. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093A Trading Volume Benchmark: Theory and Evidence.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Journal of Financial and Quantitative Analysis 34(1): 89-114.",
        "U.S. PIRG. 2013. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Top Twenty Pay-for-Delay Drugs: How Drug Industry Payoffs Delay Generics, Inflate Prices, and Hurt Consumers.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d http://www.uspirg.org/sites/pirg/files/reports/Top_Twenty_Pay_For_Delay_Drugs_USPI RG.pdf (last updated July 2013).",
        "Washington Business Information, Inc. 2012. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Mylan, Teva Settle Nuvigil Dispute Allowing Generic Launch in 2016.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d May 9.",
        "Willig, Robert D., and John P. Bigelow. 2004. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Antitrust Policy toward Agreements that Settle Patent Litigation.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d The Antitrust Bulletin 49: 655-698.",
        "Yu, Xiang, and Anjan Chatterji. 2011. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Why Brand Pharmaceutical Companies Choose to Pay Generics in Settling Patent Disputes: A Systematic Evaluation of the Asymmetric Risks in Litigation.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Northwestern Journal of Technology and Intellectual Property 10(2): 1936."
    ]
}